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Background: Poor medication adherence is a limitation in the secondary prevention of
cardiovascular diseases (CVDs) and leads to increased morbidity, mortality, and costs.
Purpose: To examine the process and effect of a nurse-led, web-based intervention based on
behavioral change strategies to improve medication adherence in patients with CVD.
Patients and methods: In this single-center, prospective, controlled clinical trial, cardio-
vascular patients were assigned to usual care, usual care plus a personalized website, or usual
care plus a personalized website and personal consultations. Primary outcome was the level
of adherence to cardiovascular medication. Data collection occurred between October 2011
and January 2015.
Results: In total, 419 patients were randomized. Just 77 patients logged on the website and
half of the invited patients attended the group consultation. Due to the limited use of the
website, we combined the results of usual care and the usual care plus website group in one
group (usual care) and compared these with the results of the group which received the nurse
intervention (intervention group). No signiﬁcant difference in adherence between the usual
care group and the intervention group was observed. The adherence level in the usual care
group was 93%, compared to 89% in the intervention group (p=0.08). 29% (usual care) and
31% (intervention group) of the patients showed a low adherence according to the Modiﬁed
Morisky Scale® (p-value=0.94). The mean necessity concern differential was 3.8 with no
differences between the two studied groups (mean 3.8 vs mean 3.9, p-value =0.86).
Conclusion: Our intervention program did not show an effect. This could indicate that
structured usual care provided to all cardiovascular patients already results in high medica-
tion adherence or that shortly after a cardiovascular event adherence is high. It could also
indicate that the program did not have enough impact because there was not enough
compliance with the intervention protocol.
Trial registration: ID number NCT01449695, approved May 2011.
Keywords: medication adherence, nurses, e-health, Health Belief Model, cardiovascular
Introduction
Cardiovascular disease (CVD) is the leading cause of death worldwide. Although
lifestyle risk factors of patients with high cardiovascular risk are monitored reg-
ularly as part of the risk-reducing programs, there is limited structural attention to
medication adherence.1 This is startling because it is known that poor medication
adherence is a major limitation in the secondary prevention of CVDs that may lead
to increased morbidity, mortality, and costs.2–4 Approximately 50% of the patients
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using medication for a chronic disorder do not adhere to
the prescribed drug regimen according to WHO.5 In
patients with CVD, adherence rates remain low, ranging
between 50 and 79%.2,6 As a consequence, in Europe an
estimated 9% of preventable CVD events can be attributed
to poor adherence to vascular medications alone.7
Current methods for improving adherence are mostly
complex and not very effective, and simple interventions
that are feasible in usual practice settings are preferred.8
There is, however, a need for more understanding in patient-
related determinants of poor adherence to medication. These
determinants can either be intentionally or unintentionally
driven. Unintentional poor adherence occurs when patients
are inclined to adhere but are not able to because of a lack of
capacity or resources. Intentional poor adherence occurs
when patients decide not to follow the agreed
recommendations.9 To be effective, interventions should
address both unintentional and intentional determinants of
poor adherence.10 Central to patients’ medication adherence
is their judgment of their personal need for taking medica-
tion. Key beliefs that inﬂuence patients’ judgment about their
medication are perception of personal needs for treatment
(necessity beliefs) and concerns about several potential nega-
tive consequences (concern beliefs).9,11,12 Though lifelong
adherence is important in CVD, absence of symptoms in the
years after an event may result in the perception that the
illness is benign. This may lead to doubts about the necessity
of continuous treatment.13 A patient-centered approach with
emphasis on patients’ perspectives might encourage CVD
patients to take their medication.14,15 The principles of the
patients’ perspective were used in the development of the
intervention under study. The intervention was, therefore,
based on the Health Belief Model (HBM)16,17 in which the
necessity–concern framework was applied9 and adapted for
the speciﬁc purpose of this trial.
Material and methods
Aim
This study aimed to evaluate the process and outcomes of
an intervention program consisting of a single group con-
sultation, two individual follow-up consultations with
a nurse, and access to an interactive personalized website,
incorporating evidence-based determinants of poor adher-
ent behavior in high-risk cardiovascular patients. The
HBM18 was chosen as the central theoretical model for
the interventions. The intervention program aims to
improve patient’s necessity and concern beliefs about
medication, which is expected to lead to better adherent
behavior in cardiovascular patients.
Design/methodology
The design of this study (with an acronym: the MIRROR
trial) has been described in detail earlier.19 The MIRROR
study is a single-center, prospective, three-arm randomized
controlled clinical trial. Patients were randomly assigned
to usual care (group I), usual care plus access to
a personalized website (group II), or usual care, access to
a personalized website plus a group consultation with
a pharmacist and a nurse, followed by two individual
nurse-led consultations at the outpatient clinic (group III).
Sample
All patients referred to the Radboud University Nijmegen
Medical Center with a new diagnosis of acute coronary
syndrome, myocardial infarction, peripheral arterial disease,
an aneurysm of the aorta or transient ischemic attacks (TIA)
or stroke over the last 6 months were included into the
hospital CVD screening program. This screening program
aims to identify cardiovascular risk factors and consists of
screening of lifestyle (smoking, diet, and exercise), blood
lipid levels, blood pressure, waist circumference, body mass
index (BMI), glucose blood levels, and a family history of
CVDs. If indicated, preventive therapies (medication and
lifestyle interventions) are structurally initiated and followed
over time.20 From this program, participants aged 18 years
and older were eligible for the MIRROR trial if they were
willing to stay in a 1-year follow-up period and provided
signed informed consent for an intervention on medication
adherence. Exclusion criteria were pregnancy reported by the
patient, severe comorbidity (eg, lung cancer, end-stage heart
failure), difﬁculties with Dutch language, or no access to
a computer.
Randomization
Patients who consented to participate were randomized
using block randomization stratiﬁed by department (neu-
rology, vascular surgery, and cardiology) in a 1:1:1 ratio
into one of the three groups. Randomization was blinded
for the principal investigator and the primary researcher.
The patient, the nurse, or the pharmacist delivering the
individual consultations could be blinded to the interven-
tion assignment in group III.
Sieben et al Dovepress
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Power calculation
The study was powered on adherence to medication
expressed as mean possession ratio (MPR). We estimated
that adherence levels at the start of the study would be
65% in each group with a SD of 30%. We hypothesized
that the intervention given in group II and the intervention
given in group III would result in an increase of 10% and
20% in adherence to treatment, resulting in a mean adher-
ence rate of 75% and 85% in group II and group III,
respectively. Consequently, the estimated group size with
a power of 80% and an alpha of 0.05 (two-sided) would be
200 in each group, resulting in 600 participants in total.
Timeline
The intervention period lasted 12 months. Within, on
average, 6 weeks after the CVD event, baseline character-
istics were collected for all patients. Follow-up outcomes
were collected at 12 months after inclusion for all patients.
Data collection
Process evaluation
As recommended by the Medical Research Council
Guidance,21 we included a process evaluation of this inter-
vention program. A process evaluation helps to understand
the relationship between how well an intervention was
delivered, the different elements of an intervention, and
the main outcomes of a trial.22,23 It furthermore improves
the validity and interpretation of these outcomes and gives
information so the intervention can be replicated.24 This
intervention program was performed at an outpatient clinic
for cardiovascular risk management in our academic hos-
pital. Nurses, who deliver the individual consultations,
already counsel cardiovascular patients in changing their
lifestyle (eg, stop smoking and losing weight) through
motivational interviewing techniques. In addressing the
problem of nonadherence as a behavioral problem, the
intervention program could ﬁt really well in the existing
clinical setting. There is also a broad recognition that
nurses have a key role in understanding and addressing
patients ‘beliefs during consultations about their
medication.
Adherence
The primary outcome of our study was adherence to cardio-
vascular medication. Adherence was based on pharmacy reﬁll
dates (PRD) of participants’ ﬁlled prescriptions obtained from
computerized pharmacy systems. Data were collected for pre-
scribed cardiovascular drugs (plated aggregation inhibitors,
lipid-modiﬁed agents, and antihypertensive drugs) for the
period of 3 years prior to a patient’s cardiovascular event and
at least 1 year after cessation of the intervention of this trial.
All prescription records included the Anatomic Therapeutic
Chemical code (ATC), the names of the dispensed drugs,
prescribed daily dose, quantity dispensed at each pharmacy
ﬁll, and the dates of the prescription ﬁlls. Adherence was
reported as the MPR for all cardiovascular medication. The
MPR was deﬁned as the number of days of treatment dis-
pensed divided by the number of days prescription reﬁlls.25
We calculated adherence levels at baseline (T1), at the end of
the intervention (T2), and at 1 year after ending the interven-
tion (T3). Patients with an adherence level of at least 80%were
considered adherent, whereas patients with an adherence level
lower than 80% were considered as nonadherent.
Secondary outcomes
Clinical responses
According to the hospital screening program, blood was
drawn from all patients to determine low-density lipopro-
tein (LDL) cholesterol levels. A recorded LDL cholesterol
level of 20% above the baseline level during follow-up
was considered as an indication of poor adherence. If
patients used antihypertensive drugs, they were classiﬁed
adherent if the systolic blood pressure was <135 mmHg
after the intervention. Target blood pressure levels were set
according to the European Society of Hypertension (ESH)
recommendations (ie, a systolic blood pressure level of
<135 mm Hg). These ofﬁce blood pressure measurements
were performed according to the recommendations of the
ESH with a validated automated device and based on
a mean of four ofﬁce measurements.26
Patient outcomes
All patients ﬁlled out the Modiﬁed Morisky Scale (MMS®)
and the Beliefs about Medicines Questionnaire (BMQ) at
baseline and at the end of the follow-up period. The MMS®
is a validated questionnaire consisting of eight items aimed
at measuring adherence.27–29 Each item accounts for 0 or 1
in case questions are answered by No or Yes, respectively.
These scores were divided into three levels of adherence:
low adherence (sum score <6), medium adherence (sum
score 6 to <8), and high adherence (sum score of 8). To
evaluate patients’ beliefs and perceptions about their med-
ication, the BMQ was used.30 Respondents stated their
degree of agreement with each individual statement about
medicines on a ﬁve-point Likert scale. The necessity–con-
cern differential (NCD) was calculated as the difference
Dovepress Sieben et al
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between necessity and concern scores and had a possible
range of −20 to 20. If the difference was positive, the
patient perceived that the beneﬁts of medication outweighed
the concerns. Contrarily, if the differential was negative, the
patient perceived more costs than beneﬁts.13,31 To separate
patients on the basis of their beliefs about the necessity of
their medication and their concerns about taking medica-
tion, the total necessity and concern scores (5–25) were split
at midpoint (thus 5–12 was considered as low and 13 t/m 25
was considered as high). Patients were then classiﬁed into
four different categories: accepting (high necessity and low
concerns), ambivalent (high necessity and high concerns),
skeptical (high concerns and low necessity), and indifferent
(low concerns and low necessity).32–34 From all patients,
the type of CVD (acute coronary syndrome, myocardial
infarction, peripheral arterial disease, an aneurysm of the
aorta, or TIA) was recorded. Also, the following baseline
and clinical characteristics were collected: age, sex, level of
education, employment status, and the country of origin.
Whether patients were new or chronic users of cardiovas-
cular medication was also registered. To classify patients as
a chronic medication user, they had to use a plated aggrega-
tion inhibitor and/or a lipid-modiﬁed agents more than 2
months before baseline according to PRD. All other patients
were classiﬁed as new users. The log-on information
expressed as the number of log-ins, times, and dates on
the personalized website of each patient were recorded.
Ethics
Written informed consent was collected from all patients
prior to entering the study. The study protocol was
approved by the local ethical committee. Approval for
this study was obtained by the local ethical committee,
the human-related research committee of the Arnhem-
Nijmegen region (CMO no 2011/062), which applied cri-
teria described in the Medical Scientiﬁc Research with
People Act (WMO), the Helsinki Declaration, the Good
Clinical Practice (GCP), EU Guideline GCP, Clinical trials
guidelines on medicinal products, and CCMO guidelines.
Data analysis
Data were analyzed based on the intention-to-treat principle
and evaluated by using SPSS, with descriptive statistics
(mean, median, and SD) being determined for all variables.
Differences between the patient groups were tested by per-
forming an ANOVA test on the outcome measures. All socio-
demographic and disease-related factors were included so they
could be taken into account as potential confounders.14,35,36 To
handle with missing data, we followed the recommendations
for eHealth research and used multiple imputation techniques
in SPSS.37 Multiple imputation is considered as the standard
procedure for dealing with missing data. It has the advantage
of incorporating auxiliary information about missing data into
the analysis, thereby reducing bias and improving accuracy.38
Analysis of multiple imputated data shows greater power and
efﬁciency than complete case analyses. Multiple imputations
make better use of available data and can generate different
results from simpler techniques.39 The datasets generated and
analyzed during this study are not publicly available due to the
Dutch privacy laws. But they are available from the corre-
sponding author on reasonable request.
Validity and reliability
This study used instruments with their validity and relia-
bility tested in previous studies.27,30,40 Participants were
randomized using block randomization. The intervention
was delivered by well-trained nurses who all had a training
speciﬁc for delivering the intervention.
Results
Process evaluation
Development of the intervention program
The intervention program consisted of a nurse-based inter-
vention providing structured information and motivational
counseling, and a personalized visualization of cardiovas-
cular risk levels on a website. The intervention was based
on evidence-based behavior change theory, the HBM16
and the necessity–concern framework.9 This necessity–
concern framework is a useful model for understanding
and addressing both unintentional and intentional
nonadherence.9 By using the BMQ,30 nurses could get
insight into the necessity and concern beliefs of their
patients and were able to tailor their consultation to the
needs of each individual patient. The HBM is based on the
understanding that a person will take health-related action
(eg, being adherent to cardiovascular medication) given
four main factors. The ﬁrst two factors are perceived
susceptibility and perceived severity, reﬂecting the under-
standing of the high personal risk and seriousness of
a condition (eg, because of the cardiovascular event in
the past, I am at greater risk for another cardiovascular
event). The third factor is perceived beneﬁts, aimed at the
belief a negative health condition can be avoided (eg,
being adherent to the cardiovascular medication can help
Sieben et al Dovepress
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to prevent another cardiovascular event). The last factor
covers the perceived barriers, cue to action, and self-efﬁ-
cacy, aimed at the belief to have the ability to successfully
undertake the recommended health action (eg, I know how
to take my medication on a daily base). The group con-
sultation with between 10 and 12 patients was chosen for
delivering knowledge and understanding of the risks.
Moreover, it also provided a gathering with other patients
(peers) in which patients were given the possibility to
discuss adherence behavior and learn from each other. In
the individual consultations, the intervention was further
tailored to each individual, so nurses were able to identify
objectives for change of (un)intentional nonadherence (or
a mix of both) and were able to address the determinants
of patients’ beliefs, perceptions and management of their
illness and medication next to patients’ skills and
memory.8 To support the individual and group consulta-
tions, an interactive and personalized website was devel-
oped. On this website, patients could see their own
cholesterol levels, blood pressure, and lifestyle (smoking,
physical activity, and eating habits) in a risk monitor.
Patients had the opportunity to ask questions by email to
their nurse and enter changes in their medication. We
choose a three-arm randomized controlled trial to deter-
mine if the website alone was effective or if group con-
sultations and individual consultations had add-on effects.
The participating nurses were trained in motivational inter-
viewing and had applied this as part of the usual care
program for several years.41 They received an extra train-
ing for this intervention.42,43
The website was expected to be effective on itself by
creating awareness (risk monitor), providing (written)
information, and tailoring of the information by the email
facility.44,45 Risk communication and the feedback of clin-
ical outcome can be provided personally and patients were
encouraged to be active in handling their disease and
medication. The website was connected to the hospital
laboratory system to provide personal clinical results.
Logging in was due to high privacy levels. Patients had
to use a special personal code and had to conﬁrm their
password with a code they received from a text message.
For developing the intervention program, we used the
recommended behavior change strategies of the HBM.
We tailored further by using the taxonomy of Abraham
and Michie46,47 and the coding manual by de Bruin to
categorize the behavior change techniques that required
to be enclosed in the intervention.46,48
For each of the components of HBM, the determinants,
techniques, and application strategy that were developed
are described in Table 1.
Uptake of the intervention
Patient enrollment and inclusion
Of a total of 1,201 patients with a cardiovascular event who
enrolled the screening program, 900 were eligible to partici-
pate in this study. Of these, 481 declined to participate. In
total, 419 patients were randomized into group I (n=133),
group II (n=138), and group III (n=148). Data collection
occurred between October 2011 and January 2015. After
randomization, 148 patients were invited to attend the
group and individual consultations, of which 79 of these
participated in the group consultation. One hundred and
thirty-four and 79 of these patients visited the ﬁrst
and second individual consultation, respectively. In total,
286 patients got access to the website and were requested
to visit the website. Seventy-seven patients of both groups
actually logged-in on the website of which only 37 logged-in
more than once. Since only a small proportion of the patients
in group II and group III logged-in on their personalized
website (34 and 43 patients for group II and group III,
respectively), it was questionable whether there could be an
effect of the website when compared to usual care. Therefore,
we decided to report the results based on two groups, in
which group I and group II combined were compared to
group III, ie, we examined the effects of the group consulta-
tion plus the extra individual consultations.
From the 419 randomized patients, reﬁll data of 260
patients were available. We used multiple imputation tech-
niques for all missing data. See Figure 1.
Results of the intervention
Baseline characteristics
At baseline, the mean age of the participants was 61 years
and 67% were male. Forty-seven percent of the partici-
pants were diagnosed with a stroke or TIA, 36% with an
acute coronary syndrome, and 17% with peripheral arterial
disease. Ninety-eight percent received an antithrombotic
agent and 94% received lipid-lowering medication after
the event. At baseline, MPR for all cardiovascular medica-
tion was 72%. According to the MMS®, 20% of all
patients were low adherent, 46% and 35% were medium
and high adherent, respectively. Mean NCD according to
the BMQ was 3.6. Mean LDL was 2.5 mmol/L and mean
systolic blood pressure was 137 mmHg. See Table 2.
Dovepress Sieben et al
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Adherence
The intervention did not show an effect on adherence to
treatment. Patients in the usual care group had an adher-
ence level of 93%, compared to 89% in the intervention
group (p-value=0.08) at T2. At T3, there also was no
signiﬁcant difference detected (adherence level was 81%
and 76%, respectively, for groups I and II with a p-value
of 0.23). Percentage of adherent patients was 86.3% in
the usual care group and 76.4% in the intervention
group (p-value=0.17) at T2. This was 65% and 57.4%
(p-value=0.38), respectively, at T3. Though we did not
see differences in adherence between the usual care and
intervention group, we observed a difference in adher-
ence in time for both groups combined. Therefore, we
performed a repeated measurement ANOVA in time
without differentiating in trial groups. At T1, at T2,
and at T3, the overall adherence was 72%, 92% and
80%, respectively. During the study period, medication
adherence increased with 20% (95% CI 0.065–0.335).
One year after this period, it declined with 12% (95%
CI 0.073–0.17).
Clinical outcomes
At T2, the mean LDL level was 2.2 mmol/L (2.5 mmol/L
at baseline) and mean systolic blood pressure was 155
mmHg (136 mmHg at baseline) for both groups. There
were no differences in LDL and blood pressure alteration
between both groups. Blood pressure was above the target
level in 76% of all patients and 12% showed a recorded
LDL cholesterol level of 20% above the baseline LDL
level (p-value between groups was 0.52 and 0.4,
respectively).
Patient outcomes
No differences between the MMS® and the BMQ were
detected at T2 between both groups. 29% (usual care) and
31% (intervention group) of the patients showed a low
adherence according to the MMS®. There were no differ-
ences between the two groups studied (p-value=0.94). The
mean NCD was 3.8 at T2. Again, no differences between
the two studied groups were present (mean 3.8 vs mean
3.9, p-value =0.86). We did observe a difference in the
four BMQ categories. In the intervention group, there was
a shift from ambivalent (from 60% at T1 to 37% at T2)
toward accepting (25% at baseline to 33% at T2). In the
usual care group, this shift was from ambivalent (63–43%)
to skeptical (4–15%) and indifferent (6–15%).T
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Differences in adherence, beliefs about medication, and
clinical outcomes are depicted in Table 3A.
The observed adherence difference expressed in time is
shown in Table 3B.
Total population eligible for CVRM-screeing between 01.10.2011 and 27.10.2013
N=1201
N=256 exclusion
N=78 co morbidity or not
speaking dutch language
N=45 missing (no reason described)
Patients asked to participate N=900
Patients consented N=419
Group I N=133 Group II N=138
Baseline screening: BP, LCHC, BMI, Lifestyle questionnaire, MMS/BMQ
Group consultation
N=79 participated
Determine lipids and BP for
website visualization
Determine lipids and BP for
website visualization
Determine lipids and BP for
website visualization +
individual consultation
N=134 visited
Determine lipids and BP for
website visualization +
individual consultation
N=79 visited
N=129 visited
N=79 visited
Logged in website
Evaluation screeing;
BP, lipid, glucoses, BMI, waist circumference, lifestyle questionnaire, MMS/BMQ
(no show 30, died 2, serious comorbidity 4, moved 1, other event 2, lost for FU 6)
Pharmacy provided PRD N=83
(no show 28, died 2, serious comorbidity 6, moved 1, other event 1, lost for FU 6)
Pharmacy provided PRD N=86
(no show 45, died 2, serious comorbidity 6, moved 2, other event 1, lost for FU 7)
Pharmacy provided PRD N=91
Group III N= 85
Group II N= 94
Group I N= 88
Logged in website
N=34 N=43
Visit one (16 weeks)Visit one (16 weeks)
Visit two (28 weeks) Visit two (28 weeks)
Group III N=148
N=188 no computer
Figure 1 Patient enrollment and participation.
Note: LCHC depicts lipoprotein analysis with determination of high density lipoproteine-cholesterol and low density lipoproteine-cholesterol calculation.
Abbreviations: BMI, body mass index; PRD,pharmacy reﬁll dates; FU, follow up; MMS, Modiﬁed Morisky Scale; BMQ, Beliefs about Medicines Questionnaire; CVRM,
cardiovascular risk management; BP, blood pressure.
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Table 3A Differences in medication adherence, beliefs about medication, and clinical outcome between usual care and intervention
groups at baseline, after intervention and at follow-up of 12 months (all after imputation)
Group I+II Usual care (UC)
N=271
Group II UC+consultations
N=148
p-valuea
Mean possesion ratiob
Total of cardiovascular medication
Baseline (T1) 0.74 0.73
After intervention (T2) 0.93 0.89 0.08
Follow up of 12 months (T3) 0.81 0.76 0.23
Per ATC-code
Baseline (T1)
Antithrombotic agents (B01) 0.77 0.73
Diuretics (C03) 0.79 0.73
Beta blocking agents (C07) 0.87 0.83
Calcium channel blockers (C08) 0.95 0.94
Agents acting angiotensin (C09) 0.80 0.79
Lipid modifying agents (C10) 0.80 0.76
After intervention (T2)
Antithrombotic agents (B01) 0.92 0.91 0.65
Diuretics (C03) 0.88 0.82 0.40
Beta blocking agents (C07) 0.91 0.91 0.89
Calcium channel blockers (C08) 0.89 0.87 0.57
Agents acting angiotensin (C09) 0.92 0.91 0.56
Lipid modifying agents (C10) 0.90 0.89 0.06
Follow up of 12 months (T3)
Antithrombotic agents (B01) 0.86 0.82 0.27
Diuretics (C03) 0.83 0.76 0.12
Beta blocking agents (C07) 0.80 0.80 0.87
Calcium channel blockers (C08) 0.93 0.91 0.34
Agents acting angiotensin (C09) 0.84 0.80 0.48
Lipid modifying agents (C10) 0.84 0.78 0.06
Adherentc
Baseline (T1) 53.5 48
After intervention (T2) 86.3 76.4 0.17
Follow up of 12 months (T3) 64.9 76.4 0.38
Modiﬁed Morisky Scaled
Baseline (T1)
Low 19.6 21.6
Medium 46.5 41.2
High 32.7 37.2
After intervention (T2)
Low 28.7 31 0.94e
Medium 38 38.5
High 33.3 30.5
Beliefs about medication questionnaire
Necessity concern differentialf
Baseline (T1) 3.7 3.4
After intervention (T2) 3.8 3.9 0.86
Categoriesg
Baseline (T1)
Accepting 27.3 25
Ambivalent 62.7 60.1
(Continued)
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Discussion
This study evaluated a nurse-led web-based intervention based
on the HBM11,16,49 and the necessity–concern framework50 on
medication adherence to treatment. Although we developed
the intervention considering the recommendations of major
reviews on medication adherence interventions,8,51–53 we did
not see an effect of the developed intervention on our main
adherence outcome. There are several explanations for the
absence of an effect of this intervention. First, all patients in
our study received the same structural cardiovascular care
according to the European Guidelines of prevention of
CVDs.20 A previous evaluation of our cardiovascular screen-
ing program showed that a structural multidisciplinary evalua-
tion and initiation of the best medical treatment in combination
with addressing unhealthy lifestyle reduces cardiovascular risk
as indicated by a reduction in smoking, alcohol consumption,
unhealthy eating, blood pressure, and LDL-cholesterol level.54
Although medication adherence was not a structural approach
in our usual care setting, the attention and screening on CVD-
risk factors may have inﬂuenced adherence to medication
adherence positively.
Second, in this study, we used pharmacy reﬁll data as
adherence measure. Reﬁll adherence rates have exten-
sively been used for the evaluation of medication adher-
ence. Compared to electronic monitoring, reﬁll data
provide researchers with a relatively simple method for
investigating adherence to medication in large
populations.55 However, due to the increasing availability
of automatic reﬁlls in the Netherlands, this measure may
represent high adherence levels, while patients do not
necessarily take their medication.10 By combining the
reﬁll data with a self-reported questionnaire, we, therefore,
Table 3A (Continued).
Group I+II Usual care (UC)
N=271
Group II UC+consultations
N=148
p-valuea
Sceptical 4.4 5.4
Indifferent 5.5 9.5
After intervention (T2)
Accepting 26.6 32.8
Ambivalent 43.2 37.1
Sceptical 14.8 17.6
Indifferent 15.2 12.6
Clinical outcomes
Systolic blood pressure (mmHg)
Baseline (T1) 136.4 136.7
After intervention (T2) 155 155 0.71
Adherenth 25 20.9 0.52
Low- density cholestrol (mmol/L)
Baseline (T1) 2.5 2.5
After intervention (T2) 2.2 2.2 0.74
Adherenti 90.4 86.4 0.4
Notes: aUsual care and usual care + are combined and compared with usual care ++ group. bMean number of days dispended divided by the mean number of days between
prescription reﬁll. cPercentage of patients (%) considered adherent according to PRD total of the cardiovascular medication (PRD was above or equal to 0.8). dPercentage of
patients (%) who had low, medium, or high adherent scores. eLow and medium adherence are combined and compared with high adherence group. fDifferences between
concern and necessity scores (means). gPercentage of patients (%) who are classiﬁed in the four different categories of the BMQ. hPercentage of patients (%) considered
adherent according to systolic blood pressure (<135 mmHg) and percentage (%) of patients using antihypertension drugs. iPercentage of patients (%) considered adherent
according to LDL level (the recorded LDL level after intervention was 20% lower of baseline LDL cholesterol).
Table 3B Differences in mean medication adherence in time
All participants (N=419) Baseline (T1) After intervention (T2) Follow-up 12 months (T3)
Mean possesion ratio
Total of cardiovascular medication
0.72 0.92* 0.80**
Notes: *p-value <0.05 relative to T1. **p-value<0.05 relative to T2.
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wanted to gain a fuller understanding of the adherence
behavior of the patients. The results of the used question-
naire also showed no differences in medication adherence
between the groups. Last, although the use of eHealth
interventions is recommended to improve healthy behavior
and for tailoring adherence interventions,44,56 the website
was rarely used by our patients. Consequently, we were
not able to study the perceived beneﬁts of our eHealth
intervention on adherence. Future studies should address
this. There are several explanations as to why patients did
not use the website. Patients had to use a special personal
code and had to conﬁrm their password with a code they
received from a text message. These complicated steps
may have inﬂuenced the use of the website negatively.
High dropout rates may be a natural and typical feature
of eHealth interventions,57 as was observed in our trial.
There were fewer patients as expected who actually used
the website and/or participated in the group consultation.
This could be an indication that the intervention might be
too intensive and experienced as a burden for patients. It
could also mean that the intervention program was not
enough exposed to enough patients to show a signiﬁcant
difference between the intervention group and the usual
care group. We developed the intervention program by
using constructs of the HBM and the necessity–concern
framework but without involving patients. By personaliz-
ing the content of the individual consultations, we believed
we tailored the intervention to the personal need of the
patients. On the other hand, the process in which the
content of the program was delivered was not tailored at
all. Maybe only tailoring the content is not enough and the
process in which the intervention is delivered also should
be more tailored. For further research, we highly recom-
mend involving patients in designing the intervention.
The study did show a difference in adherence in time for
all groups. Adherence rates were higher during the study
period and declined to levels comparable to baseline 1 year
after the end of the study. Several explanations can be
addressed for this phenomenon. First, participation in
a study may have encouraged patients to be more
adherent.9 Second, all patients who participated in this
study recently had a cardiovascular event. For these patients,
the need for adherent behavior is emerging.35,58 Yet, as the
event fades and there are no more symptoms, adherence can
also decline.2 This was also observed in our study.We looked
even further to see if there was a difference in new users of
CVRM medication and chronic users. We did observe
a relatively high cohort of chronic users in our population,
but this did not have any effect on the outcome. Although we
did not establish a difference between groups in the NCD, we
observed a shift in the categories from ambivalent toward
accepting in the intervention group; this shift was not
observed in the usual care group. In the ambivalent group,
necessity beliefs are high but concern beliefs are also high. In
the acceptance group, necessity beliefs are high but the con-
cern beliefs are low. In order to know if the change in
necessity category for the intervention group will have
a positive effect on the adherence rate over time, we need
to measure the adherence rate further in time.
Although overall adherence was relatively high at 12
months follow-up, only 20% of all patients had a systolic
blood pressure within target. The mean blood pressure was
even higher than it was at baseline. In contradiction, only
12% of all patients showed an LDL cholesterol level of 20%
above the baseline LDL level. We cannot really explain this
difference. Several major studies have demonstrated nonad-
herence to be an important cause for not reaching target
levels, as well for lipid-lowering medication as for antihy-
pertensive medication.59,60 It can be suggested that not reach-
ing the target level of systolic blood pressure is not
necessarily due to nonadherence of the medication.61–63
Limitations
The study had several shortcomings. There were chal-
lenges with recruitment and due to an organizational deci-
sion to no longer supporting the website, we had to stop
inclusion early and the original recruitment target was not
met. This may have underpowered our results. However,
the CI of the mean of the main outcome (the MPR)
showed only a very small interval from −0.005 to 0.082.
Therefore, we may assume that a larger population size
would not have made a difference in MPR between
groups. We also had to deal with missing data, especially
on the pharmacy reﬁll data. The Dutch healthcare system
does not provide a closed pharmacy system to a point of
care (like a hospital). Therefore, we were dependent on the
willingness of the pharmacists to provide us with reﬁll
data. This led to missing data. We also had a relatively
high percentage of patients who did not complete the
intervention and/or did not show up at the evaluation
screening. By using multiple imputation golden standard
for dealing with missing data, we believe we still provided
a valid result of this study.38,39 Last, the nurses who
performed the individual usual care consultations if
needed (eg, to lose weight or to quit smoking) were the
same nurses as the nurses who performed the consultations
Dovepress Sieben et al
Patient Preference and Adherence 2019:13 submit your manuscript | www.dovepress.com
DovePress
849
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
17
4.
24
8.
11
 o
n 
25
-J
un
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
in our intervention group. This and the fact that all patients
visited the same outpatient clinic while on chronic care
support may lead to inﬂuencing among the groups. In
order to prevent such contamination among the groups,
the nurses who give the usual care should be different
from those in the intervention groups.
Conclusion
Our intervention to improve medication adherence in cardi-
ovascular patients did not show an effect on improving poor
medication adherence. The intervention program was devel-
oped using the existing evidence and by applying this evi-
dence. The intervention was also developed so it could easily
be applied to the already existing structured usual care for
secondary preventive cardiovascular care. By performing
a process evaluation, we gained information that could help
future researchers to include elements of this intervention.
Elements of our intervention program could still lead to
improving medication adherence, but we were not able to
demonstrate it in this trial. This is maybe due to high adher-
ence rates in both groups and/or the limited number of
patients that complied with the intervention program.
Adherence rates after the intervention were high in both the
usual care and the intervention group. This could indicate
that the structured provided care we already deliver to all
cardiovascular patients has a positive effect on medication
adherence. Or the effect of having a cardiovascular event was
the key to better adherence.
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